INTRODUCTION
Ophthalmological complications of diabetes mellitus (DM) remain a major public health problem. Despite a significant progress in investigating the causes of diabetic retinopathy (DR) and the development of therapeutic methods, DR remains to be a leading cause of blindness among young persons suffering from DM; among working-age adults, it causes a dramatic loss in visual acuity in 5% of cases [1] .
DR is caused by chronic hyperglycemia which results in the activation of the sorbitol shunt, oxidative damages, accumulation of endproducts of glycation, microcirculation impairment, hypercoagulation, increased vascular permeability, endothelial dysfunction, activation of apoptosis, etc. [2, 3] . Multicenter clinical trials have shown the efficacy of preventive measures aimed primarily at good glycemic control, which permit to achieve 75% reduction in the risk of visual loss [4] . However, once DR has developed it usually cannot be reversed. Accumulation of pathobiochemical and pathophysiological changes resulting in retinal damages, its hypoperfusion and ischemia, which ultimately trigger the production of cytokines and growth factors [5] [6] [7] . A key growth factor mediating vascular permeability and neovascularization is a vascular endothelial growth factor (VEGF), isoform A of which is the most active and exerts many effects [8] . Retinal cells (retinal pigment epithelium, pericytes, and astrocytes) are those which, in response to hypoxic damage, actively produce VEGF [9] [10] [11] which, in turn, causes its edema and neovascularization. Eye structures of patients with DM and DR have been shown to contain higher amounts of VEGF [12] , the levels of which are decreased following retinal laser coagulation (RLC) [13] .
Nowadays, anti-VEGF agent widely used for the treatment of DR as well as the age-related macular degeneration [14, 15] , it demonstrated reducing the macular edema and blockage new vessels grow. On the other hand, VEGF mediates normal physiological processes (reparation and wound healing, ensuring cell survival, normal course of pregnancy, glomerulogenesis, vasodilatation, etc.,), the suppression of which may result in serious adverse reactions in patients with DM in particular.
The aims of this study were: (1) to investigate the association of VEGF-A concentration in the anterior chamber liquid (ACL) with vascular proliferation in patients with DR who had undergone surgical treatment for cataract and neovascular glaucoma; (2) to analyze the association of VEGF-A level in ACL with the cataract surgery outcomes.
MATERIALS AND METHODS
This study was a cross-sectional study evaluating the levels of VEGF-A and glucose in ACL of DM patients with cataract and neovascular glaucoma (NG), with a 12-month follow-up period after cataract extraction. For all patients, the levels of VEGF-A and glucose were measured in ACL, which was collected at baseline (before surgery). The samples were centrifuged, separated from the precipitate and stored at -80°C. The levels of VEGF-A were measured by the enzyme-linked immunosorbent assay (ELISA) and the glucose levels by a glucose oxidation method. Patients were examined before surgery, the day after surgery and 1, 3, 6, and 12 months after surgery.
To assess the long-term visual outcomes, the patients were monitored for 12 months after surgery. At examination performed immediately after cataract extraction (on next day), DM patients were assigned to the groups according to the verified stage of DR. After the end of the follow-up period, DR stage and visual acuity were assessed and all complications were registered.
Statistical Analysis
The descriptive statistics are presented as median (25th percentile; 75th percentile) as well as weight percentage (%) for the prevalence parameters. Visual acuity data are presented as median (95% CI). To compare more than two independent groups, Kruskal-Wallis test was used; then pairwise comparisons using MannWhitney test with the Bonferroni adjustment was performed. Qualitative data were compared and contingency tables evaluated using Chisquare test. The dependent groups were compared using Wilcoxon test. Correlation analysis was performed using Spearman's rank test (R). To identify the risk factors in the follow-up groups at the completion of the prospective phase, risk (I R ), risk difference (RD), relative risk (RR), and odds ratio (OR) with regard to the occurrence of an endpoint were calculated using the contingency tables. Kaplan-Meier survival curve was displayed based on the prospective follow-up data, and the significance of the difference was analyzed using a Cox proportional hazards regression model.
The critical significance level (P) for statistical hypothesis testing was set at \0.05.
The study protocol was approved by local ethics committee and was conducted in Number of operated eyes (n) The prevalence of DR among the operated DM patients with cataract is shown in Fig. 1 .
Post-operative examination (5-7 days after operation) has shown that no signs of DR were present in 8.2% of patients, and NPDR, PPDR, and PDR were present in 37.2%, 38.2%, and 16.4% of patients, respectively. The likelihood of PDR detection post-operation was higher by 4.5%. It should also be noted that before operation PDR was correctly diagnosed in 50% cases only because of lens opacity interfered the adequate fundus examination.
Glucose Levels in ACL
On the day of surgery, ACL glucose levels and fasting plasma glucose were similar in different groups of DM patients. However, the median of ACL glucose levels was slightly increased in the groups with severe forms of DR (from 3.08 in patients without DR to 4.85 in DM patients with neovascular glaucoma). A direct relationship exists between ACL glucose levels and fasting plasma glucose (R = 0.49, P\0.001), Table 1 . HbA 1C levels in the different groups of diabetic patients were also similar, except for the group of patients without DR (P\0.001) (in this group, DM was compensated to the highest possible degree as the patients had the lowest glucose levels both in blood and in ACL).
VEGF-A Levels in ACL
VEGF-A levels in ACL of diabetic patients were increased in the groups with more severe stages of DR. The lowest VEGF-A levels in ACL were seen in diabetic patients without signs of DR [22.75 pg/mL (10.78; 63.36)]; they were even lower than those in the control group [95.07 pg/mL 123.58) in those with PPDR (the difference with a group of patients without DR was significant, P = 0.007). In patients with PDR, VEGF-A levels in ACL attained the highest values [336.6 pg/mL (232.3; 410.74); P\0.0001]. Therefore, in diabetic patients with PDR, VEGF-A levels in ACL were three times higher than those in control groups and 15 times higher than those in diabetic patients without DR (Fig. 2) . Of interest, VEGF-A levels in ACL continue to increase with further DR progression. Indeed, in diabetic patients with NG (terminal stage of DR) these levels attained 1,634.01 pg/mL (610.69; 2657.33) and were 4.8 times higher than in diabetic patients with PDR and 17 times higher than in the control group (differences with all groups were significant, P\0.05).
Correlation analysis has shown association between VEGF-A levels and DR severity (R = 0.59, P\0.001). However, no correlations have been found between VEGF-A levels in ACL and the level of HbA 1C , GFR, blood pressure.
Visual Function in Patients with Cataract
Visual function assessments in operated diabetic patients with cataract on the next day, at 5th-7th day and at 1st, 3rd, 6th, and 12th month after surgery in the post-operative period have shown that the best results were achieved in the groups of patients with less severe stages of DR (P\0.001). Pre-operative visual acuity in groups of patients with different DR stage was similar (P = 0.31). This fact could be explained by the significant influence of lens opacity on visual acuity. The majority of patients had the hard, progressive, cortical or posterior subcapsular cataract. In groups of diabetic patients without DR, with NPDR and with PPDR, visual acuity was significantly increased post-operation and maintained at high level over 12 months (P\0.05). However, in patients with severe stages of DR, visual acuity in the delayed post-operative period gradually decreased and returned to baseline values at 12 months after operation (Fig. 3) .
Analysis of Cataract Surgery Outcomes
There is an ongoing discussion on the high-risk of complications after cataract surgery in diabetic patients. Therefore, the authors followed the patients operated for cataract for 12 months after surgery by measuring visual acuity, assessing DR stage, and monitoring the complications. Kaplan-Meier survival curve was displayed based on data obtained in the observation period: follow-up outcomes were a decrease in the visual acuity by more than 0.2, vision loss and development of NG (or rubeosis iridis). Patients treated with RLC (who Fig. 2 Median of VEGF-A levels in ACL in operated patients (pg/mL) as function of DR severity. Axis Y, VEGF-A in ACL. ACL anterior chamber liquid, DM diabetes mellitus, DR diabetic retinopathy, NPDR nonproliferative diabetic retinopathy, PPDR pre-proliferative diabetic retinopathy, PDR proliferative diabetic retinopathy, NG neovascular glaucoma, VEGF-A vascular endothelial growth factor A maintained their visual acuity), patients lost to follow-up, and patients who required eye surgery for other indications (different from follow-up outcomes) were not censored (i.e., not taken into account as patients with vision loss). As seen in Fig. 4 , the incidence of vision loss was higher in patients with high baseline VEGF-A levels in ACL. The highest incidence of these episodes was observed from month 3 to 5.
In diabetic patients with the highest VEGF-A levels in ACL (25% of all patients from the upper quartile, corresponding to patients with VEGF-A levels in ACL [137.4 pg/mL), vision loss at 12 months was observed in 25% of cases, while in patients with VEGF-A levels in ACL \137.4 pg/mL, only in 8-9% of cases. As was shown using a Cox proportional hazards regression model, these differences were statistically significant (P = 0.016).
In the overall follow-up group, 7.6% of patients developed NG by 12 months after surgery, 40% patients were treated with RLC due to severe forms of DR, and only 52.4% of patients had no complications during the postoperative period.
To evaluate the risks of NG development in diabetic patients after cataract surgery, the authors performed a variance analysis assessing each factor's contribution ( Table 2 ). The whole population was divided according to the presence of the factor studied, and the risk parameters were calculated for each factor.
Patients with high VEGF-A levels in ACL ([137.4 pg/mL) had a RR with regard to NG development of 9.62 and OR of 12.3, i.e., the risk of NG development in the post-operative period was 9.62-12.3 higher in these patients than in the others (the differences were statistically significant, P = 0.0004). Patients with low GFR (\60 mL/min) had 5.9-7 times higher risk than those who had GFR higher than 60 mL/min (P = 0.009). Other risk factors (such as, the presence of concurrent open-angle glaucoma, history of RLC, HbA 1C higher than 7.5%, marked hypertension, the presence of microalbuminuria or proteinuria) also increased the risk of NG development by 1.65-3.5 times; however, the differences did not reach statistical significance P[0.05.
DISCUSSION
Concomitant presence of DR and cataract worsens the visual prognosis in diabetic patients and makes it difficult to perform therapeutic interventions. This study has shown that lenticular opacities prevent accurate and prompt verification of DR stage, with PDR being accurately verified in 50% of cases only.
Hyperglycemia is clearly a trigger for DR development and, combined with other pathophysiological mechanisms, results in progression of retinopathy. In this study, the authors have not found any differences in ACL glucose levels, glycemia, and HbA 1C in patients with different DR stages, except for diabetic patients without DR in whom ACL glucose values and HbA 1C were at the lowest levels (differences in HbA 1C were statistically significant). This may be explained by the fact that good metabolic control prevents the occurrence of DR signs, however, if DR has already developed, the markers of carbohydrate metabolism do not correlate well with the severity of DR anymore. Because the cause of the retina neovascularization is the severe ischemia the use of some medicines (statins, antiplatelets) should be investigated carefully.
At the same time, VEGF-A levels in ACL reflected the severity of DR. These levels were significantly different in various groups of diabetic patients. VEGF-A levels in ACL increased with DR progression; the values achieved were 16-fold higher than in patients without DM and 65-fold higher than in diabetic patients without DR. Similar results were shown in previous studies [17] [18] [19] [20] [21] , which found the elevation the vitreous and aqueous [22, 23] demonstrated the elevation VEGF value in the glaucomatous eyes and the benefits of the blockage of the VEGF in the eye [24, 25] . In this way, VEGF-A levels in ACL are associated with the severity of DR.
In the current study, cataract surgery and intraocular lens implantation enhanced the [28] [29] [30] . Panretinal RLC also decreased ocular VEGF concentration and can prevent DR progression after phacoemulsification [31, 32] .
In the present study, the authors aimed to find other risk factors which could be evaluated before surgery for better visual outcomes in diabetic patients. The authors revealed that decreasing of the GFR less than 60 mL/min, significantly increased the risk of NG development in post-operative period (by 5.9-7.0 times). It can be explained by expanded circulation of the waist product and, therefore, more severe retina hypoxia which resulted to the neo-vessels formation. There have been a number of studies [33, 34] 
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